Consistently, the CXCR4 antagonists AMD3100 and CX549 were both efficient to mobilize bone marrow hematopoietic stem cells (HSCs), improving behavioral performances, reducing brain infarction, and suppressing the expression of inflammatory markers in stroke brain (48, 49). The gene discussed is CXCR4; the disease is stroke disorder.